ObjectiveThe aim of this study is twofold. First, to evaluate the long-term outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment in a clinical setting using the “treat-and-extend regimen” (TER) in patients with neovascular age-related macular degeneration (nAMD). Second, to determine the proportion of patients treated with anti-VEGF with good visual acuity (VA), i.e., vision sufficient to maintain a high level of independence.DesignWe conducted a single center retrospective review of patients with treatment-naive nAMD who were treated with anti-VEGF. Patients were treated with anti-VEGF intravitreal injections according to the TER. Patients started treatment with monthly injections of either bevacizumab (1.25 mg/0.05 mL) or ranibizumab (0.5 mg/0.05 mL) until there were no signs present of choroidal neovascularization (CNV) activity. CNV activity was determined from fundus examination and SD-OCT imaging. Follow-up administration of intravitreal injections was extended by 2-week intervals, up to a total of 14 weeks, provided no signs of CNV activity were detected. In some patients, the first treatment was replaced with aflibercept (2 mg/0.05 mL).ParticipantsOn the basis of the inclusion criterion for the study, that patients had to be treated for 5 years, a total of 101 patients were included in the study. In all patients, one eye was treated for a 5-year period, and thus we studied 101 eyes.MeasurementsBest corrected VA was analyzed at baseline and each year during the 5-year follow-up.ResultsVA improved initially after year 1 of the treatment. VA decreased in the subsequent 4 years of treatment, but remained significantly higher from year 1 to year 3 of the treatment compared to baseline values. Patients with good VA followed a similar trend: the proportion increased in the first year, and thereafter gradually decreased during the course of the 5-year follow up. At year 5, the number of patients with good VA decreased to baseline values.ConclusionTER with anti-VEGF for nAMD treatment prevents long-term severe visual loss in real-world setting and maintains patients’ VA at levels sufficient to ensure independence.
Pars plana vitrectomy (PPV) is a surgical approach mainly chosen for complex rhegmatogenous retinal detachment (RRD) repair with highly variable functional results. The aim of this analysis was to evaluate the impact of preoperative factors and postoperative optical coherence tomography (OCT) macular findings on the functional outcome of patients undergoing primary PPV for RRD. A retrospective analysis was performed on 88 eyes of 88 patients with complex RRD managed by PPV. A swept source OCT was used to obtain images at the postoperative visit at least 6 months after PPV. Hierarchical linear regression model was used to evaluate the influence of preoperative factors related to patient, ocular clinical and postoperative OCT macular findings on functional outcomes of PPV for RRD. Duration of symptoms (p = 0.031) and discontinuity of the ellipsoid zone (EZ) on OCT (p = 0.024) showed statistically significant negative correlation, while preoperative best-corrected visual acuity (BCVA; p < 0.001) showed statistically significant positive correlation to postoperative BCVA. Preoperative BCVA and duration of symptoms can be used as prognostic factors for visual outcome in patients undergoing PPV for RRD. Discontinuity of the EZ was the only postoperative OCT variable related to worse postoperative visual outcome.
Izhodišča: Ovrednotili smo anatomski in funkcionalni izid zdravljenja kompleksnega regmatogenega odstopa mrežnice z vitrektomijo pars plana (PPV). Metode: V retrospektivno raziskavo smo vključili 88 oči 88 bolnikov, ki so bili zaradi kompleksnega regmatogenega odstopa mrežnice zdravljeni s PPV. Določili smo anatomski uspeh in funkcionalni izid na podlagi korigirane vidne ostrine (VO) v celotni skupini bolnikov in v skupinah glede na status očesne leče, rumene pege in prisotnosti proliferativne vitreoretinopatije (PVR) stopnje ≥ C1. Z optično koherenčno tomografijo (OCT) rumene pege smo vsaj 6 mesecev po PPV ovrednotili prisotnost prekinitev elipsoidne cone, cistoidnega makularnega edema (CME), epiretinalne membrane (ERM) ali makularne luknje. Rezultati: Anatomski uspeh je bil po primarni PPV 93,2 %. Končni anatomski uspeh je bil dosežen pri vseh 88 bolnikih (100 %). Korigirana VO se je statistično značilno izboljšala iz VO 1,7 ± 1,2 SD logMAR pred operacijo na VO 0,6 ± 0,7 SD logMAR po operaciji (p=0,01). Med skupinama bolnikov je glede na prisotnost PVR izstopal slabši anatomski izid v skupini s PVR stopnje ≥ C1 (89,7 %). Korigirana VO se je po operaciji izboljšala pri vseh skupinah bolnikov, vendar po analizi glede na skupine statistično značilno le v skupini fakih (p=0,019), z odstopom rumene pege, (p=0,016) in s prisotnim PVR stopnje ≥ C1 (p=0,028). Končna VO je bila boljša v skupini psevdofakih (0,75 ± 1,06), v skupini bolnikov z ležečo rumeno pego (0,78 ± 1,30) in pri bolnikih brez PVR (0,80 ± 1,15 logMAR). Analiza OCT rumene pege po operaciji je pokazala prisotnost prekinitev elipsoidne cone v 39 %, CME v 15 %, ERM v 2 % in makularne luknje v 2 %. Primerjava spremenljivk OCT glede na skupine na podlagi statusa očesne leče, rumene pege in prisotnosti PVR stopnje ≥ C1 je pokazala največji delež prekinitev elipsoidne cone v skupini oči s prisotnim PVR stopnje ≥ C1 (58,6 %). Zaključek: Ugotovili smo visoko stopnjo anatomske in funkcionalne uspešnosti zdravljenja kompleksnega regmatogenega odstopa mrežnice z vitrektomijo. Funkcionalni izid je bil boljši pri bolnikih z umetno znotrajočesno lečo, pri bolnikih z ležečo rumeno pego in pri bolnikih brez PVR. Največji delež bolnikov s prekinjeno elipsoidno cono je bil v skupini bolnikov s predoperativno PVR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.